Phase 1/2 × Recruiting × Other hematologic neoplasm × Clear all CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Phase 1/2 Recruiting
152 enrolled
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Phase 1/2 Recruiting
70 enrolled
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Phase 1/2 Recruiting
97 enrolled
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations
Phase 1/2 Recruiting
58 enrolled
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Phase 1/2 Recruiting
281 enrolled
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Phase 1/2 Recruiting
200 enrolled
MB-dNPM1-TCR.1 in Relapsed/Refractory AML
Phase 1/2 Recruiting
29 enrolled
UHKT-PTC-TMI-1
Phase 1/2 Recruiting
16 enrolled
OPAL
Phase 1/2 Recruiting
144 enrolled
CaDAnCe-101
Phase 1/2 Recruiting
614 enrolled
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
Phase 1/2 Recruiting
58 enrolled
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
Phase 1/2 Recruiting
100 enrolled
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
Phase 1/2 Recruiting
120 enrolled
Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia
Phase 1/2 Recruiting
70 enrolled
A Study of BGB-11417 in Participants With Myeloid Malignancies
Phase 1/2 Recruiting
260 enrolled
cAMeLot-1
Phase 1/2 Recruiting
420 enrolled
A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
Phase 1/2 Recruiting
43 enrolled
Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Phase 1/2 Recruiting
40 enrolled
Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML
Phase 1/2 Recruiting
20 enrolled
Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia
Phase 1/2 Recruiting
84 enrolled
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Phase 1/2 Recruiting
225 enrolled
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
Phase 1/2 Recruiting
8 enrolled
Soundtrack-E
Phase 1/2 Recruiting
408 enrolled
ADAPT-HEM
Phase 1/2 Recruiting
96 enrolled
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
Phase 1/2 Recruiting
320 enrolled
Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction
Phase 1/2 Recruiting
28 enrolled
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Phase 1/2 Recruiting
960 enrolled
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
Phase 1/2 Recruiting
265 enrolled
ALLight
Phase 1/2 Recruiting
83 enrolled
QUADvance
Phase 1/2 Recruiting
178 enrolled
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Phase 1/2 Recruiting
32 enrolled
Phase I/II
Phase 1/2 Recruiting
50 enrolled
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
Phase 1/2 Recruiting
134 enrolled
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
Phase 1/2 Recruiting
27 enrolled
TITANium
Phase 1/2 Recruiting
174 enrolled
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Phase 1/2 Recruiting
606 enrolled
Phase IB/II of CPX-351 for Relapse Prevention in AML
Phase 1/2 Recruiting
24 enrolled
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
Phase 1/2 Recruiting
260 enrolled
AUGMENT-101
Phase 1/2 Recruiting
447 enrolled 6 FDA
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Phase 1/2 Recruiting
80 enrolled
A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
Phase 1/2 Recruiting
15 enrolled
MOMENTUM
Phase 1/2 Recruiting
84 enrolled
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
Phase 1/2 Recruiting
420 enrolled
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Phase 1/2 Recruiting
160 enrolled
TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
Phase 1/2 Recruiting
30 enrolled
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
Phase 1/2 Recruiting
52 enrolled
Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).
Phase 1/2 Recruiting
33 enrolled
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Phase 1/2 Recruiting
126 enrolled
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
Phase 1/2 Recruiting
96 enrolled
CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies
Phase 1/2 Recruiting
54 enrolled